COVID-19 vaccines: authorised

Vaccines authorised in the European Union (EU) to prevent COVID-19, following evaluation by the European Medicines Agency (EMA). 

EMA is not involved in advising on travel requirements in the EU, such as vaccination, quarantine or testing for travellers. 

Decisions about which COVID-19 vaccines are included, for example, in the EU Digital COVID Certificate, are taken by the EU Member States. EMA is in charge of the scientific evaluation of vaccines for EU marketing authorisation. The acceptability criteria for travel purposes are broader and can include, for example, World Health Organization (WHO) listed vaccines that have not necessarily undergone the EMA process of authorisation.

Official information on this topic is available in all EU languages at: 

Authorised COVID-19 vaccines

The table below lists the COVID-19 vaccines that can be used in the EU. 

The marketing authorisation holders for these vaccines can apply for the authorisation of a version of their vaccine that has been adapted to address coronavirus variants.

EMA is evaluating these applications in an expedited manner, using its rolling review procedure.

Information on ongoing evaluations of adapted vaccines is available under 'Key milestones' in the table below. 

VaccineMarketing authorisation holderKey milestonesMore information
COVID-19 Vaccine (inactivated, adjuvanted) ValnevaValneva Austria GmbHMarketing authorisation issued: 24/06/2022

Latest news

Safety updates

Paediatric investigation plan

NuvaxovidNovavax CZ, a.s.

Conditional marketing authorisation issued: 20/12/2022

Latest news

Safety updates

Clinical data (login required)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)AstraZeneca AB

Conditional marketing authorisation issued: 29/01/2021

Annual renewal issued: 09/11/2021


Clinical data (login required)

Spikevax (previously COVID-19 Vaccine Moderna)

Moderna Biotech Spain S.L.

Conditional marketing authorisation issued: 06/01/2021

Annual renewal issued: 04/10/2021

Start of rolling review for adapted vaccine: 17/06/2022

Start of evaluation of application for adapted vaccine: 22/07/2022


Clinical data (login required)

Comirnaty (developed by BioNTech and Pfizer)

BioNTech Manufacturing GmbH

Conditional marketing authorisation issued: 21/12/2020

Annual renewal issued: 03/11/2021

Start of rolling review for adapted vaccine: 15/06/2022

Start of evaluation of application for adapted vaccine: 22/07/2022

Clinical data (login required)

Jcovden (previously COVID-19 Vaccine Janssen)

Janssen-Cilag International NV

Conditional marketing authorisation issued: 11/03/2021

Annual renewal issued: 03/01/2022


Clinical data (login required)

For more information on how EMA evaluated these vaccines, see:

Safety updates for authorised COVID-19 vaccines

EMA monitors the safety of COVID-19 vaccines authorised in the EU extremely carefully. This enables the detection of any rare side effects that may emerge once many millions of people are vaccinated.

Safety updates on each COVID-19 vaccine are available:

Increasing manufacturing capacity

EMA is actively involved in approving new manufacturing sites to increase manufacturing capacity and supply of COVID-19 vaccines in the EU:


How useful was this page?

Add your rating
77 ratings
32 ratings
40 ratings
61 ratings
555 ratings